AIDX.US 20/20 Biolabs, Inc. Common Stock

Healthcare Health Care Equipment & Supplies USA Stocks
0.2043 USD
Close of Nov 14, 2026
0.1800 50.00
Market cap
USD 2.73M
P/E
-
P/B
1.68x
ROE
-233.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is AIDX.US undervalued?

Graham number

The Graham number of 20/20 Biolabs, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

20/20 Biolabs, Inc. Common Stock fundamental analysis

No fundamental analysis for 20/20 Biolabs, Inc. Common Stock yet.

20/20 Biolabs, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About 20/20 Biolabs, Inc. Common Stock

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. a…

Full company profile